1027076-19-2

Basic information

• Product Name: 5-tert-butyl-2-chloro-1,3-benzoxazole
• Synonyms: 5-tert-butyl-2-chloro-1,3-benzoxazole;5-(tert-Butyl)-2-chlorobenzo[d]oxazole
• CAS NO: 1027076-19-2
• Molecular Formula: C11H12ClNO
• Molecular Weight: 209.67208
• Mol File: 1027076-19-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-tert-butyl-2-chloro-1,3-benzoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-tert-butyl-2-chloro-1,3-benzoxazole(1027076-19-2)
• EPA Substance Registry System: 5-tert-butyl-2-chloro-1,3-benzoxazole(1027076-19-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1027076-19-2(Hazardous Substances Data)

Upstream product

• 53146-48-8 5-(tert-butyl)benzo[d]oxazole-2-thiol 
• 3279-07-0 4-tert-butyl-2-nitrophenol 
• 1199-46-8 2-amino-4-tert-butylphenol 

Relevant articles and documents

A new 5-HT3 receptor ligand. II. Structure-activity analysis of 5-HT3 receptor agonist action in the gut

Several modified 2-piperazinyl benzoxazole derivatives, which exhibit an agonistic effect on gastrointestinal motility, were synthesized and their effects on the contraction of guinea-pig ileum were examined. The quaternary piperazinyl benzoxazole structure has a restricted conformation and stereostructure compared to those of the other 5-HT3 receptor agonists, serotonin and meta-chlorophenylbiguanide. The mutual positions of the aromatic ring, nitrogen atom and terminal amine are considered to form the pharmacophore of the 5-HT3 receptor agonist in the gut. In the serotonin- evoked reflex bradycardia [Bezold-Jarisch (B-J) reflex] inhibition test using rats the B-J reflex-inducing ratio was different for each synthesized compound. These results suggest that, in these 5-HT3 receptor agonists, the substituents of the benzoxazole ring influence the B-J reflex-inducing activity in rats.

DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY

The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C1-C4 alkyl, or linear or branched C1-C4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents ?C(=O)-, or B represents CH when n=0 and D represents ?CH2O? or when n=1 and D represents ?O?, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.